

March 3, 2017

BSE Limited,
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

The National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (East), MUMBAI - 400 051.

Dear Sir/Madam,

Sub: <u>Disclosure pursuant to Regulation 30 of the SEBI</u>
(<u>Listing Obligations and Disclosure Requirements</u>) Regulations, 2015.

Vide letter dated February 28, 2017, we had sent to your Exchange a press release as regards receipt of final USFDA approval for Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution, 17.5 g/3.13 g/1.6 g per 6 ounces, to market a generic version of Braintree Laboratories's Suprep® Bowel Prep Kit.

We are now enclosing a Revised press release in connection with the aforesaid disclosure.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

Yours faithfully, For **LUPIN LIMITED** 

R. V. SATAM

**COMPANY SECRETARY** 

Encl.: a.a.



BSE: 500257

NSE: LUPIN

**REUTERS: LUPIN.BO** 

BLOOMBERG: LPC IN

## Lupin Receives FDA Approval for Generic Suprep® Bowel Prep Kit

Lupin is eligible for 180 days of generic drug exclusivity

Mumbai, March 03, 2017: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Sodium Sulfate, Potassium Sulfate, and Magnesium Sulfate Oral Solution, 17.5 g/3.13 g/1.6 g per 6 ounces from the United States Food and Drug Administration (FDA) to market a generic version of Braintree Laboratories's Suprep® Bowel Prep Kit.

Lupin's Sodium Sulfate, Potassium Sulfate, and Magnesium Sulfate Oral Solution, 17.5 g/3.13 g/1.6 g per 6 ounces is the AA rated generic equivalent of Braintree Laboratories's Suprep® Bowel Prep Kit. Sodium Sulfate, Potassium Sulfate, and Magnesium Sulfate Oral Solution, 17.5 g/3.13 g/1.6 g per 6 ounces is indicated for cleansing of the colon in preparation for colonoscopy in adults.

Suprep® Bowel Prep Kit had US sales of USD 207.2 million (IMS MAT December 2016).

## **About Lupin Limited**

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 5<sup>th</sup> and the 6<sup>th</sup> largest generics pharmaceutical company by market capitalization (December 31<sup>st</sup>, 2016, Bloomberg) and sales globally (September 30<sup>th</sup>, 2016, Bloomberg). The Company is the 5<sup>th</sup> largest pharmaceutical player in the US by prescriptions (4.68% market share – IMS Health, National Prescription Audit, March 2016); the 2<sup>nd</sup> largest Indian pharmaceutical company by revenues; the 6<sup>th</sup> largest generic pharmaceutical player in Japan and the 4<sup>th</sup> largest generic pharmaceutical company in South Africa (IMS Health, March 2016).

For the financial year ended 31<sup>st</sup> March, 2016, Lupin's Consolidated sales and Net profit stood at Rs. 136,539 million (USD 2.09 billion) and Rs. 22,607 million (USD 345 million) respectively. Please visit <a href="http://www.lupin.com">http://www.lupin.com</a> for more information. You could also follow us on Twitter - <a href="http://www.twitter.com/lupinlimited">www.twitter.com/lupinlimited</a>

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3<sup>rd</sup> Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

## For further information or queries please contact -

Arvind Bothra

Head – Investor Relations and M&A

Ph: +91-70 45 656 895

Email: arvindbothra@lupin.com

\*Safe Harbor Statement

Suprep® is the registered trademark of Braintree Laboratories Inc.